391 related articles for article (PubMed ID: 15078138)
21. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
Lane SW; Crawford J; Kenealy M; Cull G; Seymour JF; Prince HM; Marlton P; Gill D; Mollee PN
Leuk Lymphoma; 2006 Sep; 47(9):1813-7. PubMed ID: 17064993
[TBL] [Abstract][Full Text] [Related]
23. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
[TBL] [Abstract][Full Text] [Related]
24. An analysis of current neutropenia therapies, including pegfilgrastim.
Gabrilove JL
Clin Cornerstone; 2006; 8 Suppl 5():S19-28. PubMed ID: 17379160
[TBL] [Abstract][Full Text] [Related]
25. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
[TBL] [Abstract][Full Text] [Related]
26. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.
Lyman GH
Expert Opin Biol Ther; 2005 Dec; 5(12):1635-46. PubMed ID: 16318427
[TBL] [Abstract][Full Text] [Related]
27. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
28. Pegfilgrastim use during chemotherapy: current and future applications.
Wolf T; Densmore JJ
Curr Hematol Rep; 2004 Nov; 3(6):419-23. PubMed ID: 15496275
[TBL] [Abstract][Full Text] [Related]
29. Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.
Schwartzberg LS; Bhat G; Peguero J; Agajanian R; Bharadwaj JS; Restrepo A; Hlalah O; Mehmi I; Chawla S; Hasal SJ; Yang Z; Cobb PW
Oncologist; 2020 Aug; 25(8):e1233-e1241. PubMed ID: 32476162
[TBL] [Abstract][Full Text] [Related]
30. Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.
Donkor KN; Selim JH; Waworuntu A; Lewis K
Ann Pharmacother; 2017 Oct; 51(10):840-847. PubMed ID: 28597691
[TBL] [Abstract][Full Text] [Related]
31. Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia.
Petros WP
Pharmacotherapy; 2003 Aug; 23(8 Pt 2):1S-2S; quiz 20S-23S. PubMed ID: 12921215
[No Abstract] [Full Text] [Related]
32. Maximizing the outcomes in cancer patients receiving chemotherapy through optimal use of colony-stimulating factor.
Mucenski JW; Shogan JE
J Manag Care Pharm; 2003; 9(2 Suppl):10-4. PubMed ID: 14613339
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.
Fox E; Widemann BC; Hawkins DS; Jayaprakash N; Dagher R; Aikin AA; Bernstein D; Long L; Mackall C; Helman L; Steinberg SM; Balis FM
Clin Cancer Res; 2009 Dec; 15(23):7361-7. PubMed ID: 19920107
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
André N; Kababri ME; Bertrand P; Rome A; Coze C; Gentet JC; Bernard JL
Anticancer Drugs; 2007 Mar; 18(3):277-81. PubMed ID: 17264759
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
36. PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) augments the therapeutic effect of pegfilgrastim on gemcitabine-induced neutropenia.
Yoo N; Lee HR; Shin SH; Sohn KY; Kim HJ; Han YH; Chong S; Kim MH; Yoon SY; Kim JW
Cancer Lett; 2016 Jul; 377(1):25-31. PubMed ID: 27105612
[TBL] [Abstract][Full Text] [Related]
37. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.
George S; Yunus F; Case D; Yang BB; Hackett J; Shogan JE; Meza LA; Neumann TA; Liang BC
Leuk Lymphoma; 2003 Oct; 44(10):1691-6. PubMed ID: 14692520
[TBL] [Abstract][Full Text] [Related]
38. Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.
Lambertini M; Ferreira AR; Del Mastro L; Danesi R; Pronzato P
Expert Opin Biol Ther; 2015; 15(12):1799-817. PubMed ID: 26488491
[TBL] [Abstract][Full Text] [Related]
39. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
Aapro M; Cornes P; Abraham I
J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
[TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
